EP: 1.CheckMate 8HW: Nivolumab Plus Ipilimumab in MSI-High/dMMR Metastatic Colorectal Cancer EP: 2.EMERALD-1: Durvalumab/Bevacizumab Plus TACE in Unresectable HCC EP: 3.NETTER-2: Lu-177 Dotatate for Patients With Advanced Gastroenteropancrea...
635 Background: In the phase II CheckMate-142 trial, NIVO + low-dose IPI (1 mg/kg) provided meaningful clinical benefit in previously treated MSI-H/dMMR mCRC pts after a median follow-up of 13.4 mo. Here, we present long-term follow-up (median 25.4 mo) of these pts. Methods: Pts...
Cancers with dMMR are considered to be MSI-high (MSI-H); therefore, in the literature, the terms dMMR and MSI-H are used interchangeably; however, even though it is rare, dMMR tumors may represent MSI-low disease or even microsatellite-stable (MSS) diseases [7,8]. dMMR can be due...